News Focus
News Focus
Followers 67
Posts 2890
Boards Moderated 0
Alias Born 04/22/2022

Re: exwannabe post# 804487

Wednesday, 12/24/2025 2:42:05 PM

Wednesday, December 24, 2025 2:42:05 PM

Post# of 820577
High-Ranking Officer e❌,

That is a “funny thing” 🤔 ..And it’s actually pretty insightful! Manufacturing is the “best possible explanation” for delay of the MAA, but it also explains the delay of industry buy-in for DC technologies overall. STANDARDIZED AUTOMATION is beginning to change that & COMBO research is fueling the motivation to speed production capabilities!

Good job, Dennis & ex!



Two Keys:
🔑 Targeted
COMBOS
🔑 Scalable
MANUFACTURING






Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.

Dr. Kalinski



NWBO’s IP portfolio includes more than one pipeline product in active clinical development. For example, the aDC1 platform that NWBO licensed from Roswell Park in New York has reached PII in combo with Merck’s pembrolizumab.
NEXT GEN COMBOS will make some significant waves going forward!



Next Generation Dendritic Cell Treatments




Pitt BioForge

NWBO Acquires Advent BioServices

Roswell Park Dendritic Cell Technology & IP

Fud Flood 🌊

Bullish
Bullish

Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News